Alternative Title非糖尿病性腎性貧血ラットにおいてSGLT2阻害薬は造血効果を示さない
Note (General)Aims/introduction: Clinical studies have shown that treatment with inhibitors of sodium-glucose cotransporter 2 (SGLT2) significantly increases the hematocrit in patients with type 2 diabetes. To investigate whether SGLT2 inhibitors directly promote erythropoietin production independently on blood glucose reduction, the hematopoietic effect of the specific SGLT2 inhibitor, luseogliflozin, was examined in non-diabetic rats with renal anemia.Materials and methods: Renal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively. Luseogliflozin (10 mg/kg bodyweight) or vehicle (0.5% carboxymethyl cellulose) was then administered for 6 weeks. The hematocrit and the hemoglobin (Hb), blood urea nitrogen, plasma creatinine, and plasma erythropoietin levels were monitored.
This is the Publisher's Version of the following article: Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia; Journal of diabetes investigation; (2019) doi: 10.1111/jdi.13205, which has been published in final form at https://doi.org/10.1111/jdi.13205.
Collection (particular)国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
Date Accepted (W3CDTF)2020-08-11T22:41:34+09:00
Related MaterialThis is the Publisher's Version of the following article: Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia; Journal of diabetes investigation; (2019) doi: 10.1111/jdi.13205, which has been published in final form at https://doi.org/10.1111/jdi.13205.
Data Provider (Database)国立国会図書館 : 国立国会図書館デジタルコレクション